If most ( 70% ) of the patients on OCUL's drug can go 9 mths without another injection ...I'm not selling other than to recover part of initial investment. That will be a game changer and there will probably be a bidding war . It's all going to come down to results ( obviously ) ...is the data good enough for approval on this trial alone , or will the FDA want Sol-R ?? completed first . So theres 3 main outcomes IMHO Bad data OK data but FDA wants 2nd trial completed before considering approval Game changer data and FDA approves on 1 trial .
Sleven was more interested in EYPT IIRC ...not sure he ever added OCUL
Market Data 
Markets 
AI
